Base de dados : MEDLINE
Pesquisa : E01.370.225.812.505 [Categoria DeCS]
Referências encontradas : 1291 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 130 ir para página                         

  1 / 1291 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29446280
[Au] Autor:Stepanenko LA; Savchenkov MF; Ilina SV; Anganova EV; Savilov ED
[Ti] Título:[An assessment of the immune status of the children population as a marker of technogenic pollution of the environment].
[So] Source:Gig Sanit;95(12):1129-33, 2016.
[Is] ISSN:0016-9900
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:This article describes results of the immunological study of school-aged children residing in cities with different levels of the technogenic air pollution. Children from cities with the highest level of the technogenic pollution had a high number of immature neutrophils (band cells) and eosinophils. The children living in these ecologically unfavorable areas have presented a reduction of T-cell antigen receptor CD3, CD4, CD8, CD20, CD16, CD95. This indicates to that both T-cell and B-cell immunity is suppressed. The decline of the phagocytic function in neutrophils indicates to the suppression of the nonspecific host defense mechanisms also.
[Mh] Termos MeSH primário: Poluentes Atmosféricos
Linfócitos B/imunologia
Exposição Ambiental
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Poluentes Atmosféricos/efeitos adversos
Poluentes Atmosféricos/análise
Criança
Exposição Ambiental/efeitos adversos
Exposição Ambiental/análise
Exposição Ambiental/prevenção & controle
Feminino
Seres Humanos
Imunocompetência/efeitos dos fármacos
Masculino
Monitorização Imunológica/métodos
Monitorização Imunológica/estatística & dados numéricos
População
Receptores de Antígenos de Linfócitos T/análise
Serviços de Saúde Escolar/organização & administração
Serviços de Saúde Escolar/estatística & dados numéricos
Sibéria/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Air Pollutants); 0 (Receptors, Antigen, T-Cell)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180216
[St] Status:MEDLINE


  2 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29431946
[Au] Autor:Kryuchkova EN; Saarkoppel LM; Yatsyna IV
[Ti] Título:[Features of immune response in chronic exposure to industrial aerosols].
[So] Source:Gig Sanit;95(11):1058-61, 2016.
[Is] ISSN:0016-9900
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:There are considered features of disorders of the immune response in chronic exposure to dust aerosols. The detected changes of indices of the immune status of employees of the dust dangerous occupations and patients with chronic dust pathology of the lungs were unidirectional in the character, which is probably caused by manifestations of nonspecific response of the immune system to the dust factor. The deterioration of cellular immunity, humoral immunity and cytokine profile predisposes to the occurrence of immunopathologic states, contributing to the development of caused by both worksite and occupation pathology.
[Mh] Termos MeSH primário: Aerossóis
Poluentes Ocupacionais do Ar
Doenças Profissionais
Exposição Ocupacional
[Mh] Termos MeSH secundário: Adaptação Fisiológica/imunologia
Adulto
Aerossóis/efeitos adversos
Aerossóis/análise
Poluentes Ocupacionais do Ar/efeitos adversos
Poluentes Ocupacionais do Ar/análise
Citocinas/sangue
Poeira/análise
Poeira/prevenção & controle
Seres Humanos
Exposição por Inalação/efeitos adversos
Exposição por Inalação/análise
Exposição por Inalação/prevenção & controle
Subpopulações de Linfócitos
Masculino
Meia-Idade
Monitorização Imunológica/métodos
Monitorização Imunológica/estatística & dados numéricos
Doenças Profissionais/diagnóstico
Doenças Profissionais/etiologia
Doenças Profissionais/imunologia
Doenças Profissionais/prevenção & controle
Exposição Ocupacional/efeitos adversos
Exposição Ocupacional/análise
Exposição Ocupacional/prevenção & controle
Saúde do Trabalhador
Federação Russa/epidemiologia
Estatística como Assunto
Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Air Pollutants, Occupational); 0 (Cytokines); 0 (Dust)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180213
[St] Status:MEDLINE


  3 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28741618
[Au] Autor:Fridman WH; Zitvogel L; Sautès-Fridman C; Kroemer G
[Ad] Endereço:Cancer, Immune Control and Escape Team, INSERM UMRS 1138, Cordeliers Research Centre.
[Ti] Título:The immune contexture in cancer prognosis and treatment.
[So] Source:Nat Rev Clin Oncol;14(12):717-734, 2017 Dec.
[Is] ISSN:1759-4782
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously untreatable malignancies. A growing awareness exists of the fact that the success of chemotherapy and radiotherapy, in which the patient's disease can be stabilized well beyond discontinuation of treatment (and occasionally is cured), also relies on the induction of a durable anticancer immune response. Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response. As a result, the immune contexture, which is determined by the density, composition, functional state and organization of the leukocyte infiltrate of the tumour, can yield information that is relevant to prognosis, prediction of a treatment response and various other pharmacodynamic parameters. Several complementary technologies can be used to explore the immune contexture of tumours, and to derive biomarkers that could enable the adaptation of individual treatment approaches for each patient, as well as monitoring a response to anticancer therapies.
[Mh] Termos MeSH primário: Imunoterapia/métodos
Linfócitos do Interstício Tumoral/imunologia
Neoplasias/imunologia
Neoplasias/terapia
Evasão Tumoral
Microambiente Tumoral
[Mh] Termos MeSH secundário: Animais
Biomarcadores Tumorais/metabolismo
Seres Humanos
Linfócitos do Interstício Tumoral/metabolismo
Linfócitos do Interstício Tumoral/patologia
Monitorização Imunológica
Neoplasias/metabolismo
Neoplasias/patologia
Valor Preditivo dos Testes
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171204
[Lr] Data última revisão:
171204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1038/nrclinonc.2017.101


  4 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28740126
[Au] Autor:Korpal M; Puyang X; Jeremy Wu Z; Seiler R; Furman C; Oo HZ; Seiler M; Irwin S; Subramanian V; Julie Joshi J; Wang CK; Rimkunas V; Tortora D; Yang H; Kumar N; Kuznetsov G; Matijevic M; Chow J; Kumar P; Zou J; Feala J; Corson L; Henry R; Selvaraj A; Davis A; Bloudoff K; Douglas J; Kiss B; Roberts M; Fazli L; Black PC; Fekkes P; Smith PG; Warmuth M; Yu L; Hao MH; Larsen N; Daugaard M; Zhu P
[Ad] Endereço:H3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA. Manav.korpal@outlook.com.
[Ti] Título:Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
[So] Source:Nat Commun;8(1):103, 2017 07 24.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority of patients fail to respond, suggesting existence of complementary immune evasion mechanisms. Here, we report that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion in MIBC. Recurrent mutations in RXRα at serine 427 (S427F/Y), through conformational activation of the PPARγ/RXRα heterodimer, and focal amplification/overexpression of PPARγ converge to modulate PPARγ/RXRα-dependent transcription programs. Immune cell-infiltration is controlled by activated PPARγ/RXRα that inhibits expression/secretion of inflammatory cytokines. Clinical data sets and an in vivo tumor model indicate that PPARγ /RXRα impairs CD8 T-cell infiltration and confers partial resistance to immunotherapies. Knockdown of PPARγ or RXRα and pharmacological inhibition of PPARγ significantly increase cytokine expression suggesting therapeutic approaches to reviving immunosurveillance and sensitivity to immunotherapies. Our study reveals a class of tumor cell-intrinsic "immuno-oncogenes" that modulate the immune microenvironment of cancer.Muscle-invasive bladder cancer (MIBC) is a potentially lethal disease. Here the authors characterize diverse genetic alterations in MIBC that convergently lead to constitutive activation of PPARgamma/RXRalpha and result in immunosurveillance escape by inhibiting CD8+ T-cell recruitment.
[Mh] Termos MeSH primário: Evasão da Resposta Imune/imunologia
Monitorização Imunológica
PPAR gama/imunologia
Receptor X Retinoide alfa/imunologia
Neoplasias da Bexiga Urinária/imunologia
[Mh] Termos MeSH secundário: Animais
Linfócitos T CD8-Positivos/imunologia
Linfócitos T CD8-Positivos/metabolismo
Linhagem Celular Tumoral
Citocinas/genética
Citocinas/imunologia
Citocinas/metabolismo
Perfilação da Expressão Gênica/métodos
Células HCT116
Seres Humanos
Immunoblotting
Imunoterapia/métodos
Mediadores da Inflamação/imunologia
Mediadores da Inflamação/metabolismo
Camundongos
Microscopia de Fluorescência
Mutação/imunologia
Invasividade Neoplásica
PPAR gama/química
PPAR gama/genética
Multimerização Proteica/imunologia
Receptor X Retinoide alfa/química
Receptor X Retinoide alfa/genética
Neoplasias da Bexiga Urinária/genética
Neoplasias da Bexiga Urinária/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cytokines); 0 (Inflammation Mediators); 0 (PPAR gamma); 0 (Retinoid X Receptor alpha)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-00147-w


  5 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29020010
[Au] Autor:Smith SG; Harris SA; Satti I; Bryan D; Walker KB; Dockrell HM; McShane H; Ho MM
[Ad] Endereço:Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
[Ti] Título:Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials.
[So] Source:PLoS One;12(10):e0184391, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cellular immunological assays are important tools for the monitoring of responses to T-cell-inducing vaccine candidates. As these bioassays are often technically complex and require considerable experience, careful technology transfer between laboratories is critical if high quality, reproducible data that allows comparison between sites, is to be generated. The aim of this study, funded by the European Union Framework Program 7-funded TRANSVAC project, was to optimise Standard Operating Procedures and the technology transfer process to maximise the reproducibility of three bioassays for interferon-gamma responses: enzyme-linked immunosorbent assay (ELISA), ex-vivo enzyme-linked immunospot and intracellular cytokine staining. We found that the initial variability in results generated across three different laboratories reduced following a combination of Standard Operating Procedure harmonisation and the undertaking of side-by-side training sessions in which assay operators performed each assay in the presence of an assay 'lead' operator. Mean inter-site coefficients of variance reduced following this training session when compared with the pre-training values, most notably for the ELISA assay. There was a trend for increased inter-site variability at lower response magnitudes for the ELISA and intracellular cytokine staining assays. In conclusion, we recommend that on-site operator training is an essential component of the assay technology transfer process and combined with harmonised Standard Operating Procedures will improve the quality, reproducibility and comparability of data produced across different laboratories. These data may be helpful in ongoing discussions of the potential risk/benefit of centralised immunological assay strategies for large clinical trials versus decentralised units.
[Mh] Termos MeSH primário: Ensaios Clínicos como Assunto
Monitorização Imunológica/métodos
Transferência de Tecnologia
Vacinas/imunologia
[Mh] Termos MeSH secundário: Bioensaio
Seres Humanos
Indicadores e Reagentes
Interferon gama/metabolismo
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Indicators and Reagents); 0 (Vaccines); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184391


  6 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28892076
[Au] Autor:Eyer K; Doineau RCL; Castrillon CE; Briseño-Roa L; Menrath V; Mottet G; England P; Godina A; Brient-Litzler E; Nizak C; Jensen A; Griffiths AD; Bibette J; Bruhns P; Baudry J
[Ad] Endereço:Laboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
[Ti] Título:Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring.
[So] Source:Nat Biotechnol;35(10):977-982, 2017 Oct.
[Is] ISSN:1546-1696
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Studies of the dynamics of the antibody-mediated immune response have been hampered by the absence of quantitative, high-throughput systems to analyze individual antibody-secreting cells. Here we describe a simple microfluidic system, DropMap, in which single cells are compartmentalized in tens of thousands of 40-pL droplets and analyzed in two-dimensional droplet arrays using a fluorescence relocation-based immunoassay. Using DropMap, we characterized antibody-secreting cells in mice immunized with tetanus toxoid (TT) over a 7-week protocol, simultaneously analyzing the secretion rate and affinity of IgG from over 0.5 million individual cells enriched from spleen and bone marrow. Immunization resulted in dramatic increases in the range of both single-cell secretion rates and affinities, which spanned at maximum 3 and 4 logs, respectively. We observed differences over time in dynamics of secretion rate and affinity within and between anatomical compartments. This system will not only enable immune monitoring and optimization of immunization and vaccination protocols but also potentiate antibody screening.
[Mh] Termos MeSH primário: Imunoglobulina G/metabolismo
Monitorização Imunológica/métodos
Análise de Célula Única/métodos
[Mh] Termos MeSH secundário: Animais
Células CHO
Calibragem
Cricetinae
Cricetulus
Imunização
Camundongos Endogâmicos C57BL
Fenótipo
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170912
[St] Status:MEDLINE
[do] DOI:10.1038/nbt.3964


  7 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28763465
[Au] Autor:Karade SK; Kulkarni SS; Ghate MV; Patil AA; Londhe R; Salvi SP; Kadam DB; Joshi RK; Rewari BB; Gangakhedkar RR
[Ad] Endereço:HIV Drug Resistance Laboratory, National AIDS Research Institute (ICMR), Pune, India.
[Ti] Título:Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.
[So] Source:PLoS One;12(8):e0181889, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The free antiretroviral therapy (ART) program in India still relies on the clinico-immunological monitoring for diagnosis of treatment failure. As the nucleoside reverse transcriptase inhibitor (NRTI) backbone is shared in first- and second-line regimens, accumulation of drug resistant mutations (DRMs) can compromise the efficacy of NRTI. This study was undertaken to describe the pattern of HIV DRMs following immunological monitoring and investigate its impact on the cycling of NRTI between first- and second-line ART. METHODS AND FINDINGS: This cross-sectional study was performed at a state-sponsored ART clinic of Pune city in western India between January and June 2016. Consecutive adults receiving first-line ART with immunological failure (IF) were recruited for plasma viral load (PVL) estimation. Randomly selected 80 participants with PVL >1000 copies/mL underwent HIV drug resistance genotyping. Of these, 75 plasma sample were successfully genotyped. The median CD4 count and duration of ART at the time of failure were 98 (IQR: 61.60-153.50) cells/µL and 4.62 (IQR: 3.17-6.15) years, respectively. The prevalence of NRTI, non-NRTI, and major protease inhibitor resistance mutations were 89.30%, 96%, and 1.33%, respectively. Following first-line failure, sequences from 56.67% of individuals indicated low- to high-level resistance to all available NRTI. The proportion of sequences with ≥2 thymidine analogue mutations (TAMs) and ≥3 TAMs were 62.12% and 39.39%, respectively. An average of 1.98 TAMs per sequence were observed following IF as compared to 0.37 TAMs per sequence following targeted PVL monitoring at 12 months of ART from a prior study; this difference was significant (p<0.001). CONCLUSION: The option of cycling of NRTI analogues between first- and second-line regimens would no longer be effective if individuals are followed-up by immunological monitoring due to accumulation of mutations. Introduction of routine PVL monitoring is a priority for the long-term sustainability of free ART program in India.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/farmacologia
Farmacorresistência Viral
Infecções por HIV/tratamento farmacológico
Monitorização Imunológica
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fármacos Anti-HIV/uso terapêutico
Terapia Antirretroviral de Alta Atividade
Contagem de Linfócito CD4
Estudos Transversais
Farmacorresistência Viral/genética
Feminino
Genótipo
HIV-1/efeitos dos fármacos
HIV-1/genética
Seres Humanos
Sistema Imunitário
Índia
Masculino
Mutação
Filogenia
Inibidores da Transcriptase Reversa/farmacologia
Inibidores da Transcriptase Reversa/uso terapêutico
Timidina/genética
Resultado do Tratamento
Carga Viral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Reverse Transcriptase Inhibitors); VC2W18DGKR (Thymidine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181889


  8 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28725958
[Au] Autor:Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
[Ad] Endereço:Department of Orthopaedic Surgery, Massachusetts General Hospital-Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
[Ti] Título:Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
[So] Source:Clin Orthop Relat Res;475(12):3071-3081, 2017 Dec.
[Is] ISSN:1528-1132
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Giant cell lesions are locally aggressive intraosseous neoplasms with capacity to metastasize. The role of immune surveillance in the pathophysiology of giant cell lesions is poorly understood, and understanding what role the immune system plays in giant cell lesions may lead to the development of more effective treatment. The aim of this study was to explore the role of immune surveillance in giant cell lesions by examining the expression of the HLA class I and class II antigens and tumor infiltrating lymphocytes. In addition, we examined the role of the immune modulating surface antigen B7-H3, which belongs to the B7 superfamily, a group of molecules that modulates T-cell responses. QUESTIONS/PURPOSES: (1) Is an immune response elicited by giant cell lesions? (2) Do clinically relevant human leukocyte antigen (HLA) defects exist in giant cell lesions? (3) Is B7-H3 a clinically relevant immune modulator? METHODS: The study sample was derived from the population of patients presenting to the Massachusetts General Hospital for evaluation and management of giant cell lesions from 1993 to 2008. We included patients with histologically confirmed giant cell lesions with a minimum followup of 6 months. Patients with systemic diseases (n = 4 [3%]), syndromes associated with giant cell lesions (n = 4 [3%]), and those without sufficient followup (n = 26 [19%]), inadequate records (n = 7 [5%]), or inadequate tissue available (n = 2 [1%]) were excluded. Tissue microarray, containing 288 tissue cores for 93 patients, was carefully constructed. This contained tissue from 45 patients with maxillofacial lesions, 38 with aggressive and seven with nonaggressive lesions, and 48 patients with axial and appendicular lesions, 30 with aggressive lesions and 18 with nonaggressive lesions. The population mean age was 28 ± 12 years and the duration of followup was 4 ± 3 years. The tissue microarray was immunohistochemically stained with monoclonal antibodies specific for HLA classes I and II and B7-H3 antigens and analyzed for tumor infiltrating lymphocytes. Antigen expression was examined in multinucleated giant cells and mononuclear stromal cells. The results were correlated with local invasion and tumor aggressiveness, which is based on accepted staging criteria. RESULTS: Tumor infiltrating lymphocytes were detected in all the tumors. The mean number of CD8+ T cell infiltration was lower in aggressive tumors (median, 4.8; interquartile range [IQR], 0.4-13.4), when compared with nonaggressive tumors (median, 15.8; IQR, 4.3-46.3; p = 0.007). HLA class I antigens were highly expressed by multinucleated giant cells in all tumors, but were lightly expressed on mononuclear stromal cells in 53% (45 of 84) to 73% (56 of 77) of tumors. HLA class I antigen low expression in mononuclear stromal cells was associated with tumor aggressiveness (odds ratio [OR], 4.3; p = 0.005). Low HLA class I expression combined with low CD8+ T cell infiltration was most highly associated with tumor aggressiveness (OR, 7.81; p = 0.011). B7-H3 antigen was expressed in 36.9% mononuclear stroma cells and also was associated with local tumor invasion (OR, 1.36; p < 0.001). Similarly, giant cell lesions with high B7-H3 expression and low CD8+ tumor infiltrating lymphocytes were associated with increased tumor aggressiveness (OR, 8.89; p = 0.0491). CONCLUSIONS: Locally aggressive giant cell lesions are associated with low HLA class 1 antigen expression, low CD8+T cell infiltration, and high expression of the immune modulator B7-H3. CLINICAL RELEVANCE: Failure of immune surveillance implies that there may be an opportunity to target aspects of the immune surveillance machinery to treat giant cell lesions.
[Mh] Termos MeSH primário: Antígenos B7/imunologia
Biomarcadores Tumorais/imunologia
Neoplasias Ósseas/imunologia
Linfócitos T CD8-Positivos/imunologia
Tumor de Células Gigantes do Osso/imunologia
Antígenos HLA/imunologia
Linfócitos do Interstício Tumoral/imunologia
Monitorização Imunológica/métodos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Neoplasias Ósseas/patologia
Boston
Feminino
Tumor de Células Gigantes do Osso/patologia
Hospitais Gerais
Seres Humanos
Estudos Longitudinais
Masculino
Razão de Chances
Valor Preditivo dos Testes
Prognóstico
Fatores de Risco
Fatores de Tempo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (B7 Antigens); 0 (Biomarkers, Tumor); 0 (CD276 protein, human); 0 (HLA Antigens)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171117
[Lr] Data última revisão:
171117
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1007/s11999-017-5451-1


  9 / 1291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28594749
[Au] Autor:Schachtner T; Stein M; Reinke P
[Ad] Endereço:1 Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany. 2 Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany. 3 Berlin Institute of Health (BIH)-Charité and Max-Delbrück Center, Berlin, Germany.
[Ti] Título:CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
[So] Source:Transplantation;101(10):e315-e325, 2017 Oct.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Detectable cytomegalovirus (CMV)-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have been attributed to an absence of circulating antibodies despite CMV sensitization. The diagnostic value of CMV-specific T cells, however, needs to be implemented in risk stratification for CMV replication. METHODS: Three hundred twenty-six KTRs were studied and classified with respect to CMV serostatus and presence of CMV-specific T cells. Samples were collected pretransplantation, at +1, +2, and +3 months posttransplantation. CMV-specific T cells directed to CMV-IE1 and CMV-pp65 were measured by interferon-γ Elispot assay. RESULTS: Nineteen (28%) of 67 D+R- KTRs showed pretransplant CMV-specific T cells. Although no differences were observed for CMV replication, KTRs with CMV-specific T cells presented with lower initial and peak CMV loads (P < 0.05). KTRs with decreasing/undetectable CMV-IE1-specific T cells pretransplantation and posttransplantation were at greatest risk of CMV replication. KTRs with stable/increasing CMV-IE1-specific T cells from pretransplantation to posttransplantation, however, showed low risk of CMV replication (P < 0.001). One hundred sixty-two (80%) of 203 R+ KTRs showed pretransplant CMV-specific T cells. Decreasing/undetectable CMV-IE1-specific T cells from pretransplantation and posttransplantation identified those R+ KTRs at increased risk of CMV replication (65/80 KTRs; 81%; P < 0.001). CONCLUSIONS: Despite CMV prophylaxis, D+R- KTRs are at greatest risk of CMV disease. Our data suggest that monitoring CMV-specific T cell kinetics from pretransplantation to posttransplantation, particularly directed to CMV-IE1, offers superior risk stratification compared with CMV serostatus alone.
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Infecções por Citomegalovirus/imunologia
Citomegalovirus/imunologia
Transplante de Rim
Linfócitos T/imunologia
Doadores de Tecidos
[Mh] Termos MeSH secundário: Adulto
Idoso
Aloenxertos
Antivirais/administração & dosagem
Biomarcadores/sangue
Citomegalovirus/efeitos dos fármacos
Citomegalovirus/genética
Infecções por Citomegalovirus/diagnóstico
Infecções por Citomegalovirus/tratamento farmacológico
Infecções por Citomegalovirus/mortalidade
ELISPOT
Feminino
Seres Humanos
Testes de Liberação de Interferon-gama
Estimativa de Kaplan-Meier
Transplante de Rim/efeitos adversos
Transplante de Rim/mortalidade
Masculino
Meia-Idade
Monitorização Imunológica
Valor Preditivo dos Testes
Estudos Retrospectivos
Medição de Risco
Fatores de Risco
Testes Sorológicos
Linfócitos T/efeitos dos fármacos
Linfócitos T/virologia
Fatores de Tempo
Resultado do Tratamento
Carga Viral
Replicação Viral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Antiviral Agents); 0 (Biomarkers)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001825


  10 / 1291 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28518214
[Au] Autor:Behnam Sani K; Sawitzki B
[Ad] Endereço:Institute of Medical Immunology, Charité Universitaetsmedizin Berlin, Berlin, Germany.
[Ti] Título:Immune monitoring as prerequisite for transplantation tolerance trials.
[So] Source:Clin Exp Immunol;189(2):158-170, 2017 Aug.
[Is] ISSN:1365-2249
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Ever since its first application in clinical medicine, scientists have been urged to induce tolerance towards foreign allogeneic transplants and thus avoid rejection by the recipient's immune system. This would circumvent chronic use of immunosuppressive drugs (IS) and thus avoid development of IS-induced side effects, which are contributing to the still unsatisfactory long-term graft and patient survival after solid organ transplantation. Although manifold strategies of tolerance induction have been described in preclinical models, only three therapeutic approaches have been utilized successfully in a still small number of patients. These approaches are based on (i) IS withdrawal in spontaneous operational tolerant (SOT) patients, (ii) induction of a mixed chimerism and (iii) adoptive transfer of regulatory cells. Results of clinical trials utilizing these approaches show that tolerance induction does not work in all patients. Thus, there is a need for reliable biomarkers, which can be used for patient selection and post-therapeutic immune monitoring of safety, success and failure. In this review, we summarize recent achievements in the identification and validation of such immunological assays and biomarkers, focusing mainly on kidney and liver transplantation. From the published findings so far, it has become clear that indicative biomarkers may vary between different therapeutic approaches applied and organs transplanted. Also, patient numbers studied so far are very small. This is the main reason why nearly all described parameters lack validation and reproducibility testing in large clinical trials, and are therefore not yet suitable for clinical practice.
[Mh] Termos MeSH primário: Sobrevivência de Enxerto
Imunossupressores/uso terapêutico
Transplante de Fígado
Monitorização Imunológica/métodos
Tolerância ao Transplante
[Mh] Termos MeSH secundário: Animais
Biomarcadores
Seres Humanos
Imunossupressores/efeitos adversos
Transplante Homólogo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170803
[Lr] Data última revisão:
170803
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1111/cei.12988



página 1 de 130 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde